- Home
- ELDN vs NVCT Comparison
ELDN vs NVCT Comparison
Compare ELDN & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELDN
- NVCT
- Stock Information
- Founded
- ELDN 2004
- NVCT 2020
- Country
- ELDN United States
- NVCT United States
- Employees
- ELDN N/A
- NVCT N/A
- Industry
- ELDN Biotechnology: Pharmaceutical Preparations
- NVCT Medicinal Chemicals and Botanical Products
- Sector
- ELDN Health Care
- NVCT Health Care
- Exchange
- ELDN Nasdaq
- NVCT Nasdaq
- Market Cap
- ELDN 140.3M
- NVCT 119.4M
- IPO Year
- ELDN N/A
- NVCT 2022
- Fundamental
- Price
- ELDN $4.07
- NVCT $4.90
- Analyst Decision
- ELDN Strong Buy
- NVCT Strong Buy
- Analyst Count
- ELDN 1
- NVCT 1
- Target Price
- ELDN $16.00
- NVCT $21.00
- AVG Volume (30 Days)
- ELDN 1.0M
- NVCT 303.6K
- Earning Date
- ELDN 11-12-2024
- NVCT 11-05-2024
- Dividend Yield
- ELDN N/A
- NVCT N/A
- EPS Growth
- ELDN N/A
- NVCT N/A
- EPS
- ELDN N/A
- NVCT N/A
- Revenue
- ELDN N/A
- NVCT N/A
- Revenue This Year
- ELDN N/A
- NVCT N/A
- Revenue Next Year
- ELDN N/A
- NVCT N/A
- P/E Ratio
- ELDN N/A
- NVCT N/A
- Revenue Growth
- ELDN N/A
- NVCT N/A
- 52 Week Low
- ELDN $1.11
- NVCT $4.69
- 52 Week High
- ELDN $5.54
- NVCT $12.10
- Technical
- Relative Strength Index (RSI)
- ELDN 51.95
- NVCT 35.71
- Support Level
- ELDN $3.76
- NVCT $4.75
- Resistance Level
- ELDN $4.17
- NVCT $5.49
- Average True Range (ATR)
- ELDN 0.39
- NVCT 1.14
- MACD
- ELDN -0.15
- NVCT -0.52
- Stochastic Oscillator
- ELDN 18.45
- NVCT 3.02
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
About NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.